Literature DB >> 23613258

High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting.

Huanan Li1, Shaoquan Bian, Yihang Huang, Jie Liang, Yujiang Fan, Xingdong Zhang.   

Abstract

pH-sensitive pullulan-doxorubicin (DOX) conjugates were synthesized by attaching DOX onto pullulan derivate through hydrazone bond that was stable under neutral environment but readily cleaved under mildly acidic condition. By changing the feed ratio of DOX to the pullulan derivate, conjugates with drug-loading content up to 30 wt % were obtained. In aqueous solution, the conjugates spontaneously formed uniform core-shell structured nanoparticles with DOX as core and pullulan as shell. The diameters of the nanoparticles ranged from 50 to 110 nm according to the drug-loading content. In vitro releasing experiments showed that more than 75% DOX released within 2 h at pH 5.0, while less than 15% DOX released after 12 h at pH 7.4. This pH-responsive manner of DOX release might assist the quick diffusion of DOX from the acidic endosome/lysosome and the intracellular transfer into the nucleus. Pullulan on the nanoparticles surface provided the nanoparticles with active targeting property to hepatic cells through specific interaction with asialoglycoprotein receptors on the membrane of hepatic cells, without the necessity of introducing any extra ligand. These pullulan-DOX conjugate nanoparticles were expected to be promising drug delivery system for liver targeting antitumor chemotherapy.
Copyright © 2013 Wiley Periodicals, Inc., a Wiley Company.

Entities:  

Keywords:  anti‐cancer; hepatic targeting; nanoparticles; pH‐sensitive; pullulan

Mesh:

Substances:

Year:  2013        PMID: 23613258     DOI: 10.1002/jbm.a.34680

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  7 in total

1.  Bio-Responsive Carriers for Controlled Delivery of Doxorubicin to Cancer Cells.

Authors:  Gheorghe Fundueanu; Marieta Constantin; Mihaela Turtoi; Sanda-Maria Bucatariu; Bogdan Cosman; Maria Anghelache; Geanina Voicu; Manuela Calin
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

Review 2.  Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.

Authors:  Erika Dosekova; Jaroslav Filip; Tomas Bertok; Peter Both; Peter Kasak; Jan Tkac
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

3.  Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.

Authors:  Yonglong Jin; Yi Wang; Xiguang Liu; Jing Zhou; Xintong Wang; Hui Feng; Hong Liu
Journal:  Drug Des Devel Ther       Date:  2020-11-25       Impact factor: 4.162

4.  Synthesis of Europium-Doped Fluorapatite Nanorods and Their Biomedical Applications in Drug Delivery.

Authors:  Haifeng Zeng; Xiyu Li; Muyang Sun; Sufan Wu; Haifeng Chen
Journal:  Molecules       Date:  2017-05-06       Impact factor: 4.411

5.  Development of dual-targeted nano-dandelion based on an oligomeric hyaluronic acid polymer targeting tumor-associated macrophages for combination therapy of non-small cell lung cancer.

Authors:  Bingjie Wang; Wei Zhang; Xiudi Zhou; Mengna Liu; Xiaoya Hou; Ziting Cheng; Daquan Chen
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

6.  Local application of doxorubicin- loaded Iron oxid nanoparticles and the vascular disrupting agent via the hepatic artery: chemoembolization-photothermal ablation treatment of hepatocellular carcinoma in rats.

Authors:  Hongjun Yuan; Xin Li; Jing Tang; Min Zhou; Fengyong Liu
Journal:  Cancer Imaging       Date:  2019-11-04       Impact factor: 3.909

7.  Preparation of a pH-responsive chitosan-montmorillonite-nitrogen-doped carbon quantum dots nanocarrier for attenuating doxorubicin limitations in cancer therapy.

Authors:  Erfan Rahmani; Mehrab Pourmadadi; Sohrab Ali Ghorbanian; Fatemeh Yazdian; Hamid Rashedi; Mona Navaee
Journal:  Eng Life Sci       Date:  2022-09-13       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.